STRIDES PHARMA SCIENCE Surges by 5%; BSE HEALTHCARE Index Up 1.9%
March 26, 2020 09:36 AM

STRIDES PHARMA SCIENCE share price has zoomed 5% and is presently trading at Rs 346.

Meanwhile, the BSE HEALTHCARE Index is at 11,668 (up 1.9%).

Among the top Gainers in the BSE HEALTHCARE Index today are STRIDES PHARMA SCIENCE (up 5.5%) and AJANTA PHARMA (up 7.6%).

FORTIS HEALTHCARE (down 0.4%) and SYNGENE INTERNATIONAL (down 0.5%) are among the top losers today.

Over the last one year, STRIDES PHARMA SCIENCE has moved down from Rs 437 to Rs 346, registering a loss of Rs 90 (down 22.8%).

On the other hand, the BSE HEALTHCARE has moved down from 14,114 to 11,668, loss of 2,446 points (down 17.5%) during the last 12 months.

The top gainers among the BSE HEALTHCARE Index stocks during this same period were ABBOTT INDIA (up 94.1%), J.B.CHEMICALS (up 47.8%) and IPCA LABS (up 36.3%).

What About the Benchmark Indices?

The BSE Sensex is at 29,084 (up 1.9%).

The top gainers among the BSE Sensex stocks today are INDUSIND BANK (up 10.0%), AXIS BANK (up 8.6%) and INFOSYS (up 5.4%). Other gainers include TECH MAHINDRA (up 4.6%) and HDFC (up 4.4%). The most traded stocks in the BSE Sensex are SBI and ICICI BANK.

In the meantime, NSE Nifty is at 8,478 (up 1.9%). The top gainers in the NSE Nifty include INDUSIND BANK (up 10.0%), AXIS BANK (up 9.3%) and INFOSYS (up 5.4%). Other gainers include TECH MAHINDRA (up 4.8%) and HDFC (up 4.7%) are among the top gainers in NSE Nifty.

Over the last 12 months, the BSE Sensex has moved down from 37,809 to 29,084, registering a loss of 8,725 points (down 23.11%).

STRIDES PHARMA SCIENCE Financial Update...

STRIDES PHARMA SCIENCE net profit stood at Rs 1 billion for the quarter ended December 2019, compared to a profit of Rs 316 million a year ago. Net Sales declined 7.8% to Rs 7.3 billion during the period as against Rs 7.9 billion in October-December 2018.

For the year ended March 2018, STRIDES PHARMA SCIENCE reported 58.6% decrease in net profit to Rs 1.3 billion compared to net profit of Rs 3.2 billion during FY17.

Revenue of the company grew 3.0% to Rs 28 billion during FY18.

The current Price to earnings ratio of STRIDES PHARMA SCIENCE, based on rolling 12 month earnings, stands at 8.0x.